These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19772371)

  • 1. Emerging cognitive enhancing drugs.
    Buccafusco JJ
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):577-89. PubMed ID: 19772371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition.
    Buccafusco JJ; Terry AV
    J Pharmacol Exp Ther; 2000 Nov; 295(2):438-46. PubMed ID: 11046074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cognitive remediation and cognitive assistive technologies in schizophrenia].
    Sablier J; Stip E; Franck N
    Encephale; 2009 Apr; 35(2):160-7. PubMed ID: 19393385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs.
    Studzinski CM; Araujo JA; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):489-98. PubMed ID: 15795058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physostigmine reverses cognitive dysfunction caused by moderate hypoxia in adult mice.
    Bekker A; Haile M; Gingrich K; Wenning L; Gorny A; Quartermain D; Blanck T
    Anesth Analg; 2007 Sep; 105(3):739-43. PubMed ID: 17717233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
    Nuechterlein KH; Robbins TW; Einat H
    Schizophr Bull; 2005 Oct; 31(4):870-4. PubMed ID: 16150960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial.
    Kim J; Chung SY; Park S; Park JH; Byun S; Hwang M; Oh DS; Choi H; Kim MY; Bu YC; Doré S; Whang WW; Kim H
    Pharmacol Biochem Behav; 2008 Oct; 90(4):517-24. PubMed ID: 18550156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chinese herbal medicine for Mild Cognitive Impairment and Age Associated Memory Impairment: a review of randomised controlled trials.
    May BH; Yang AW; Zhang AL; Owens MD; Bennett L; Head R; Cobiac L; Li CG; Hugel H; Story DF; Xue CC
    Biogerontology; 2009 Apr; 10(2):109-23. PubMed ID: 18716893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of mild cognitive impairment: value of citicoline].
    Abad-Santos F; Novalbos-Reina J; Gallego-Sandín S; García AG
    Rev Neurol; 2002 Oct 1-15; 35(7):675-82. PubMed ID: 12389156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial.
    Prakash J; Kotwal A; Prabhu H
    J ECT; 2006 Sep; 22(3):163-8. PubMed ID: 16957530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMPA receptor potentiators as cognitive enhancers.
    O'Neill MJ; Dix S
    IDrugs; 2007 Mar; 10(3):185-92. PubMed ID: 17351873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacologic treatment for cognitive disorders: an update].
    Lestage P
    Therapie; 2000; 55(4):507-12. PubMed ID: 11098728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verbal memory.
    Sumiyoshi T
    Handb Exp Pharmacol; 2015; 228():237-47. PubMed ID: 25977085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
    Floresco SB; Geyer MA; Gold LH; Grace AA
    Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.